Omicron spawn XBB.1.5, also known as “Kraken,” now dominates the U.S. COVID variant scene, comprising an estimated 61% of cases, according to federal health data released Friday.
But there’s now a new player being tracked by the U.S. Centers for Disease Control and Prevention that could give Kraken a run for its money. CH.1.1, or “Orthrus,” was estimated to comprise 1.5% of U.S. cases as of Friday. Another Omicron spawn, it was named after a mythical two-headed cattle dog killed by Hercules, by Australian variant tracker Mike Honey.
Not much is known about the relatively new strain, levels of which have been rising globally since November. Like other “high flying” COVID variants, it has the potential to be more transmissible, evade immunity from vaccine and infection, and cause more severe disease.
What’s more, it features a concerning mutation seen in the deadly Delta variant that generally isn’t seen in Omicrons—one that could make it even more daunting of a foe. While CH.1.1 isn’t a “Deltacron”—a recombinant, or combination, of Delta and Omicron—it’s a prime example of convergent evolution, a process through which COVID variants evolve independently but pick up the same mutations.
It’s anyone’s best guess as to how CH.1.1 will play out in various countries throughout the world, including the U.S., Dr. Michael Osterholm, director of the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP), tells Fortune.
“I don’t think we have a real sense of what variants to be concerned about and which not to be,” he says.
Case in point: XBB.1.5, which “started out looking like it was going to be a very serious challenge, in terms of COVID” in the U.S. But after attaining dominance in the Northeast, “it just began to peter out throughout the rest of the country,” where it hasn’t risen as swiftly, he says.
“We’ve seen this before: What might appear to be a challenging variant turns out not to be a real challenge.”
The bottom line, according to Osterholm: Anyone who thinks they can tell you what the future of the pandemic looks like—and make no mistake, we’re still in a pandemic, he says—“probably has a bridge to sell you.”
Lack of crystal ball aside, here’s what we know about the variant under monitoring by the World Health Organization.
Where and when was it discovered?
CH.1.1 emerged in Southeast Asia this fall and is now responsible for more than a quarter of infections in parts of the United Kingdom and New Zealand, according to a preprint paper released last week by researchers at Ohio State University.
Its prevalence has risen sharply since November, and it now comprises about 10% of COVID samples sequenced each day around the globe, according to outbreak.info, a community repository of COVID information.
The variant is among those being monitored by the WHO, the international health organization said in a Wednesday report.
What countries has it been located in?
New Zealand is seeing the bulk of CH.1.1 cases right now, according to outbreak.info. There, it’s responsible for more than a third of sequenced cases. Other hotspots include Hong Kong and Papua New Guinea—it comprises around a quarter of cases in each country. It’s behind slightly less than a fifth of cases in Cambodia and Ireland.
Why is it so concerning?
XBB.1.5 continues to be the most transmissible COVID strain yet, according to a Jan. 19 report from variant tracker Cornelius Romer, computational biologist at the University of Basel in Switzerland, and others. But CH.1.1 is worth watching, he says. Like XBB.1.5, it’s highly transmissible, with levels doubling every two weeks or so.
CH.1.1 also binds well to ACE2 receptors, the site where COVID infects human cells, according to Ohio State researchers. That means it has the potential to override—at least partially—antibody immunity from prior infection and vaccination, as well as to cause more severe disease. It may be able to out-perform other competitive Omicron strains in these arenas due to a concerning L452R mutation seen in Delta, but generally not in Omicron.
The Ohio State researchers used a lab-created version of CH.1.1 and examined how well serum from 14 healthcare workers—who had received between two and four doses of the original vaccine, and the new Omicron booster—neutralized it. They found that the workers’ sera created 17 times fewer antibodies against CH.1.1 as they did against BA.4 and BA.5.
CH.1.1 and another new variant, CA.3.1, are more immune evasive than XBB and BQ subvariants, the researchers wrote, calling the finding “astonishing.”
How did it evolve?
CH.1.1 is a descendent of BA.2.75, a variant that was dubbed “Centaurus” this summer but eventually fizzled out.
Most dominant COVID strains right now are descendents of either BA.5, which swept the world this summer, or BA.2.75. The variant “family” is important to note, experts say, as recent exposure to BA.2.75 or BA.5—or one of their spawn—may offer some temporary protection against infection from that family.
For example: If you were recently exposed to a BA.5 variant, you may be less vulnerable to new BA.5 variants for a time, but more vulnerable to BA.2.75 variants, and vice versa. (Of note, XBB.1.5 is also a descendent of BA.2.75.)
But with COVID, there are exceptions to every rule, it seems: Japan just saw back-to-back BA.5 waves that caused deaths there to skyrocket to an all-pandemic high, Osterholm notes.
Will the new Omicron COVID booster protect me?
Protection offered by the original COVID vaccine is waning, the Ohio State researchers wrote. They recommended the new Omicron booster but noted that it will offer less protection against CH.1.1 and CA.3.1 than it will against other variants like XBB and BQ.1.1.
https://fortune.com/well/2023/01/27/meet-orthus-ch11-new-omcrion-covid-variant-delta-mutation-deltacron-convergent-evolution/
China is tracking ‘Orthrus’ – an emerging, more
transmissible Covid variant
Published: 5:00pm, 1 Feb, 2023
The Omicron subvariant CH. 1.1, also known as “Orthrus”,
which is becoming increasingly prevalent in Britain and the United States, is
unlikely to cause another wave of outbreaks in the mainland in the near future,
Chinese health authorities said.
The most prevalent variants in China continue to be BA. 5.2
and BF. 7, but 24 cases of CH. 1.1, a more transmissible subvariant, have
been reported
in China in the past three months, authorities said.
“Despite an increased ability to resist immune responses and a higher transmissibility, which might increase breakthrough infection and reinfection risks, the population in China has a high level of neutralising antibodies,” the Chinese Centre for Disease Control and Prevention (CDC) said in a statement on Tuesday night.
“There is a certain
effect on cross protection [the degree of immunity conferred by previous
infections], and it will not cause a large-scale domestic outbreak in the short
term,” authorities said in the statement, adding that vulnerable groups
including elderly and unvaccinated people should step up protection.
Orthrus, named after a two-headed dog from Greek mythology
that was killed by the hero Heracles, has raised global concern because of a
particular mutation that it carries – known as L452R – which experts believe
increases the variant’s
immunity to current vaccines, similar to the mutation in the earlier
Delta variant.
However, the CDC said that the same mutation found in CH.
1.1 is also present in other subvariants like BA. 5.3 and BA. 5.1.3, and it is
still unclear if the lineage could cause more severe symptoms of the disease.
The first case of CH. 1.1 in China was detected in November
in the city of Tianjin, near Beijing, and was imported from Thailand, according
to authorities.
The 23 other cases were imported from 15 other
regions, and no local cases have been reported so far.
The emerging variant was first identified in India last July
and is now present in 67 countries, accounting for more than 6 per cent of
genomic sequence data reported globally, authorities said, citing statistics
from international genomic database GISAID.
As of the first week of January, CH. 1.1 infections and its sub lineage accounted for about 25 per cent of the total infections in the UK, according to the latest infection survey released by the country’s Office for National Statistics.
While XBB. 1.5 continues to dominate cases
in the US, CH. 1.1 is now the fifth most prevalent lineage in the country,
according to official data.
According to a preprint paper published by researchers at
the Ohio State University, CH. 1.1’s ability to evade neutralising antibodies
is “extraordinary”.
Their study of serums, the part of blood that contains
antibodies, found that CH. 1.1 variants are “highly
resistant” to both monovalent and bivalent mRNA vaccinations, as well
as the antibodies produced by previous BA.4 and BA.5 infections.
Chen Cao, a researcher at China’s CDC, reaffirmed on Monday
that BA. 5.2 and BF. 7 remain the dominant variants in China, adding that no
other “advantageous variants” have been found so far that could become
dominant.
·
No comments:
Post a Comment